Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral Medical has the GF Score of 11, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Spectral Medical
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Spectral Medical (TSX:EDT) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Spectral Medical GF Score Related Terms
TSX:EDT vs TMO, DHR, IDXX: GF Score Comparison
For the Diagnostics & Research subindustry, Spectral Medical's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral Medical GF Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's GF Score distribution charts can be found below:
* The bar in red indicates where Spectral Medical's GF Score falls into.
Spectral Medical (TSX:EDT) has a GF Score of 11 as of Jul. 15, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Spectral Medical and its competitors. This is 74% below median its historical median of 42.00. Over the past decade, Spectral Medical's GF Score has ranged from 11.00 to 64.00.
Is Spectral Medical's GF Score too high?
Spectral Medical's current GF Score of 11 is 74% below median its 10-year median of 42.00. Over the past 10 years, this metric has ranged from a low of 11.00 to a high of 64.00. Overall, Spectral Medical has a GF Score™ of 11/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's GF Score compare to TMO and DHR?
Spectral Medical's GF Score of 11 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Spectral Medical's own GF Score has ranged from 11.00 to 64.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Diagnostics & Research company?
A good GF Score depends on the Medical Diagnostics & Research industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Spectral Medical and its competitors. Spectral Medical's current GF Score is 11, which is 74% below median its own 10-year median of 42.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (TSX:EDT) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.92, compared to a current price of C$1.36 — trading 47.8% above its estimated fair value. The current GF Score is 11, which is 74% below median its 10-year median of 42.00. Spectral Medical's overall GF Score™ is 11/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Spectral Medical (TSX:EDT), the current GF Score is 11 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral Medical (TSX:EDT) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued.
The current stock price of C$1.36 is trading 47.8% above its estimated GF Value™ of C$0.92.
GuruFocus considers Spectral Medical to be Significantly Overvalued.
Key valuation signals for TSX:EDT:
GF Score: 11 (74% below median its 10-year median of 42.00)
GF Value™: C$0.92 vs. price of C$1.36 (47.8% above fair value)
No single metric tells the full story. See the TSX:EDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
11GF Score
Get the complete analysis for TSX:EDT
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:EDT has been successfully added to your 
